Celularity Inc. received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC confirming that Celularity has regained…
Celularity Inc (CELU) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 11, 2026, Celularity Inc. (“Celularity”) received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that Celularity has regained compliance with the minimum bid price requirement
How this was made
The 30-second read
Why it matters
The 8‑K filing confirms the company has met the required thresholds, closing the compliance issue but noting an outstanding reporting deficiency.
Market read
Compliance news can trigger a modest price reaction in small‑cap stocks; investors may reassess risk exposure.
What to watch
The lingering periodic reporting deficiency could still pose a risk if not resolved promptly.
Background
Celularity Inc. (NASDAQ: CELU) previously fell out of compliance with Nasdaq's bid price and market value rules, raising delisting concerns.
Ticker impact
Celularity Inc. regained compliance with Nasdaq's minimum bid price and market value requirements, closing the listing deficiency.
Potential short-term upside as the stock clears a compliance hurdle; price may rise modestly.
The filing is the first public disclosure of the compliance regain; such news often triggers a brief rally in small‑cap stocks.
Market effects
May lift sentiment for other small‑cap biotech and life‑science firms facing Nasdaq compliance issues.
Limited to U.S. Nasdaq‑listed micro‑caps; no broader regional effect.
Minimal global impact; relevance confined to investors tracking Nasdaq compliance.
Counterpoint
Some investors may view the compliance regain as a short‑term bump and could take profits quickly.
Key entities
- companyCelularity Inc.
Biotech firm listed on Nasdaq, ticker CELU.
- regulatory_bodyNasdaq Listing Qualifications Staff
Entity that monitors and enforces Nasdaq listing standards.
